ATCO Pharma Human Health was established in 2017, building on decades of manufacturing excellence, quality assurance, and GMP-compliant operations that had long distinguished ATCO in the animal health sector. Entering the Egyptian pharmaceutical market with its respiratory brand Tussistop, the company embarked on a strategic journey to deliver innovative, high-quality, and affordable healthcare solutions that address the country’s most prevalent medical needs.

Since its launch, ATCO has expanded into four key therapeutic areas: Cardiometabolic Care, Pain Management, Gastrointestinal Health, and Respiratory Care. Guided by a vision to improve patient outcomes and quality of life, the company has consistently selected some of the most recent molecules, advanced formulations, and differentiated product forms available in each therapeutic category. This innovation-driven approach enables ATCO to lead market trends while maintaining affordability, ensuring broader patient access to effective modern therapies.

The Cardiometabolic franchise has become a cornerstone of the company’s success, earning strong physician confidence and establishing one of Egypt’s leading anti-diabetic brands. ATCO further supports the healthcare community through continuous medical education programs and scientific partnerships with leading experts across cardiology, diabetes, nephrology, and endocrinology.

Today, ATCO Human Health has evolved into a trusted multi-therapeutic partner for healthcare professionals across Egypt. With annual sales approaching EGP 950 million and a rapidly growing market presence, the company remains committed to advancing healthcare through innovation, quality, accessibility, and patient-centered value.